All In MedTech

Device Trial Radar · NCT07258290

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,859 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,859

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Jun 2029

Study completion Jun 2033

Sponsor

Lead sponsor
TeleflexPublic (TFX)
Sponsor type
Industry
First posted
Dec 2, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system

Conditions

  • Coronary Disease
  • Heart Diseases
  • Cardiovascular Diseases
  • Arteriosclerosis
  • Arterial Occlusive Diseases
  • Vascular Diseases
  • Chest Pain
  • Pain
  • Neurologic Manifestations
  • Signs and Symptoms
  • Pathological Conditions, Signs and Symptoms
  • Coronary Artery Disease
  • Myocardial Ischemia
  • Acute Coronary Syndrome
  • Angina Pectoris

Interventions

  • Freesolve RMSDevice

    Freesolve Sirolimus-Eluting Coronary Resorbable Magnesium Scaffold (RMS) System, a drug-eluting balloon-expandable resorbable scaffold

  • Xience DESDevice

    Xience Everolimus Eluting Stent System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target Lesion Failure (TLF) rate at 12 months post-index procedureTime frame: 12 months

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Baylor Scott & White The Heart Hospital - Dallas

    Dallas, Texas · Recruiting

  • The Heart Hospital Baylor Plano

    Plano, Texas · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.